Formulation and in vitro efficacy of liposomes containing the Hsp90 inhibitor 6BrCaQ in prostate cancer cells

International Journal of Pharmaceutics

Volumn 499, Issue 1-2, 2016, Pages 101-109

  Sauvage, Félix ^a   Franzè, Silvia ^a,b   Bruneau, Alexandre ^c   Alami, Mouad ^c   Denis, Stéphanie ^a   Nicolas, Valérie ^d   Lesieur, Sylviane ^a   Legrand, François Xavier ^a   Barratt, Gillian ^a   Messaoudi, Samir ^c   Vergnaud Gauduchon, Juliette ^a  

^a UNIV PARIS SUD   (France)

^b UNIVERSITY OF MILAN   (Italy)

^c CNRS   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Apoptosis; Cell cycle; Hsp90; Liposomes; Migration; Novobiocin analog

Indexed keywords

6 BROMO 3 (4 METHOXYPHENYLCARBOXAMIDE)QUINOLEIN 2 ONE; CHAPERONE; DOXORUBICIN; GELDANAMYCIN; HEAT SHOCK PROTEIN 90 INHIBITOR; LIPOSOME; UNCLASSIFIED DRUG; 3-AMINOQUINOLEIN-2-ONE; ANTINEOPLASTIC AGENT; HEAT SHOCK PROTEIN 90; PHOSPHOLIPID; QUINOLONE DERIVATIVE;

APOPTOSIS; ARTICLE; CELL CYCLE M PHASE; CELL MIGRATION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG EFFICACY; DRUG FORMULATION; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPID BILAYER; PHOSPHOLIPID VESICLE; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; ANTAGONISTS AND INHIBITORS; CELL MOTION; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG POTENTIATION; MALE; PATHOLOGY; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CALORIMETRY, DIFFERENTIAL SCANNING; CELL LINE, TUMOR; CELL MOVEMENT; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG SYNERGISM; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LIPOSOMES; MALE; PHOSPHOLIPIDS; PROSTATIC NEOPLASMS; QUINOLONES;

EID: 84954477415     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2015.12.053     Document Type: Article

References (40)

1. T.M. Allen, and L.G. Cleland Serum-induced leakage of liposome contents Biochim. Biophys. Acta 597 2 1980 418 426
2. D. Audisio, S. Messaoudi, J.-F. Peyrat, J.-D. Brion, and M. Alami A general copper powder-catalyzed ullmann-type reaction of 3-Halo-4(1H)-quinolones with various nitrogen-containing nucleophiles J. Org. Chem. 76 12 2011 4995 5005
3. D. Audisio, S. Messaoudi, L. Cegielkowski, J.-F. Peyrat, J.-D. Brion, D. Methy-Gonnot, C. Radanyi, J.-M. Renoir, and M. Alami Discovery and biological activity of 6BrCaQ as an inhibitor of the Hsp90 protein folding machinery ChemMedChem 6 5 2011 804 815
4. D. Audisio, D. Methy-Gonnot, C. Radanyi, J.-M. Renoir, S. Denis, F. Sauvage, J. Vergnaud-Gauduchon, J.-D. Brion, S. Messaoudi, and M. Alami Synthesis and antiproliferative activity of novobiocin analogues as potential Hsp90 Inhibitors Eur. J. Med. Chem. 83 2014 498 507
5. T.-C. Chou Drug combination studies and their synergy quantification using the chou-talalay method Cancer Res. 70 2 2010 440 446
6. M.-T. Dimanche-Boitrel, H. Pelletier, P. Genne, J.-M. Petit, C.L. Grimellec, P. Canal, C. Ardiet, G. Bastian, and B. Chauffert Confluence-dependent resistance in human colon cancer cells: role of reduced drug accumulation and low intrinsic chemosensitivity of resting cells Int. J. Cancer 50 5 1992 677 682
7. D.C. Drummond, O. Meyer, K. Hong, D.B. Kirpotin, and D. Papahadjopoulos Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors Pharmacol. Rev. 51 4 1999 691 744
8. G. Gregoriadis, and C. Davis Stability of liposomes in vivo and in vitro is promoted by their cholesterol content and the presence of blood cells Biochem. Biophys. Res. Commun. 89 4 1979 1287 1293
9. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 5 2011 646 674
10. D. Hoekstra, and G. Scherphof Effect of fetal calf serum and serum protein fractions on the uptake of liposomal phosphatidylcholine by rat hepatocytes in primary monolayer culture Biochim. Biophys. Acta 551 1 1979 109 121
11. G. Jego, A. Hazoumé, R. Seigneuric, and C. Garrido Targeting heat shock proteins in cancer Cancer Lett. 332 2 2013 275 285
12. A. Kamal, L. Thao, J. Sensintaffar, L. Zhang, M.F. Boehm, L.C. Fritz, and F.J. Burrows A high-affinity conformation of Hsp90confers tumour selectivity on Hsp90 inhibitors Nature 425 6956 2003 407 410
13. A.L. Klibanov, K. Maruyama, V.P. Torchilin, and L. Huang Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes FEBS Lett. 268 1 1990 235 237
14. T.-H. Lin, H.-H. Liu, T.-H. Tsai, C.-C. Chen, T.-F. Hsieh, S.-S. Lee, Y.-J. Lee, W.-C. Chen, and C.-H. Tang Ccl2 increases αvβ3 integrin expression and subsequently promotes prostate cancer migration Biochim. Biophys. Acta BBA - Gen. Subj. 1830 10 2013 4917 4927
15. R.D. Loberg, L.L. Day, J. Harwood, C. Ying, St L.N. John, R. Giles, C.K. Neeley, and K.J. Pienta CCL2 is a potent regulator of prostate cancer cell migration and proliferation Neoplasia 8 7 2006 578 586
16. X. Lu, L. Xiao, L. Wang, and D.M. Ruden Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs Biochem. Pharmacol. 83 8 2012 995 1004
17. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, and K. Hori Tumor vascular permeability and the epr effect in macromolecular therapeutics: a review J. Control. Release 65 1-2 2000 271 284
18. S. Maillard, T. Ameller, J. Gauduchon, A. Gougelet, F. Gouilleux, P. Legrand, V. Marsaud, E. Fattal, B. Sola, and J.-M. Renoir Innovative drug delivery nanosystems improve the anti-tumor activity in vitro and in vivo of anti-estrogens in human breast cancer and multiple myeloma J. Steroid Biochem. Mol. Biol. 94 1-3 2005 111 121
19. S. Messaoudi, D. Audisio, J.-D. Brion, and M. Alami Rapid access to 3-(N-Substituted) -aminoquinolin-2 (1H)-ones using palladium-catalyzed CN bond coupling reaction Tetrahedron 63 41 2007
20. S. Messaoudi, J. Peyrat, J. Brion, and M. Alami Recent advances in Hsp90 inhibitors as antitumor agents Anticancer Agents Med. Chem. 8 7 2008 761 782
21. Y. Miyata, H. Nakamoto, and L. Neckers The therapeutic target Hsp90 and cancer hallmarks Curr. Pharm. Des. 19 3 2013 347 365
22. S. Modi, A. Stopeck, H. Linden, D. Solit, S. Chandarlapaty, N. Rosen, G. D'Andrea, M. Dickler, M.E. Moynahan, S. Sugarman, W. Ma, S. Patil, L. Norton, A.L. Hannah, and C. Hudis HSP90 Inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab Clin. cancer res. 17 15 2011 5132 5139
23. J.F. Nagle Theory of the main lipid bilayer phase transition Annu. Rev. Phys. Chem. 31 1 1980 157 196
24. A. Novell, C. Al Sabbagh, J.-M. Escoffre, C. Gaillard, N. Tsapis, E. Fattal, and A. Bouakaz Focused ultrasound influence on calcein-loaded thermosensitive stealth liposomes Int. J. Hyperth. Off. J. Eur. Soc. Hyperthermic Oncol. North Am. Hyperth. Group 31 4 2015 349 358
25. I. Ogihara-Umeda, and S. Kojima Cholesterol enhances the delivery of liposome-encapsulated gallium-67 to tumors Eur. J. Nucl. Med. 15 9 1989 612 617
26. E. Oldfield, and D. Chapman Dynamics of lipids in membranes: heterogeneity and the role of cholesterol FEBS Lett. 23 3 1972 285 297
27. S. Pacey, M. Gore, D. Chao, U. Banerji, J. Larkin, S. Sarker, K. Owen, Y. Asad, F. Raynaud, M. Walton, I. Judson, P. Workman, and T.A. Eisen Phase II. Trial of 17-Allylamino, 17-Demethoxygeldanamycin (17-AAG, Tanespimycin) in patients with metastatic melanoma Invest. New Drugs 30 1 2012 341 349
28. H.M. Patel, N.S. Tuzel, and B.E. Ryman Inhibitory effect of cholesterol on the uptake of liposomes by liver and spleen Biochim. Biophys. Acta BBA - Gen. Subj. 761 2 1983 142 151
29. L.H. Pearl, and C. Prodromou Structure and in vivo function of Hsp90 Curr. Opin. Struct. Biol. 10 1 2000 46 51
30. V. Plassat, C. Wilhelm, V. Marsaud, C. Ménager, F. Gazeau, J.-M. Renoir, and S. Lesieur Anti-estrogen-loaded superparamagnetic liposomes for intracellular magnetic targeting and treatment of breast cancer tumors Adv. Funct. Mater. 21 1 2011 83 92
31. V. Plassat, J.M. Renoir, G. Autret, V. Marsaud, and C. Ménager Systemic magnetic targeting of pure-antiestrogen-loaded superparamagnetic nanovesicles for effective therapy of hormone- dependent breast cancers J. Bioanal. Biomed. 5 2013 028 035
32. R. Scherz-Shouval, S. Santagata, M.L. Mendillo, L.M. Sholl, I. Ben-Aharon, A.H. Beck, D. Dias-Santagata, M. Koeva, S.M. Stemmer, L. Whitesell, and S. Lindquist The Reprogramming of tumor stroma by HSF1 is a potent enabler of mali gnancy Cell 158 3 2014 564 578
33. S.C. Semple, A. Chonn, and P.R. Cullis Influence of cholesterol on the association of plasma proteins with liposomes Biochemistry (Mosc.) 35 8 1996 2521 2525
34. A.V. Snigireva, V.V. Vrublevskaya, Y.Y. Skarga, Y.V. Evdokimovskaya, and O.S. Morenkov Effect of heat shock protein 90 (Hsp90) on migration and invasion of human cancer cells in vitro Bull. Exp. Biol. Med. 157 4 2014 476 478
35. S. Tsutsumi, and L. Neckers Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis Cancer Sci. 98 10 2007 1536 1539
36. S.Z. Usmani, R. Bona, and Z. Li 17 AAG for HSP90 inhibition in cancer - from bench to bedside Curr. Mol. Med. 9 5 2009 654 664
37. J.R. Valbuena, G.Z. Rassidakis, P. Lin, C. Atwell, G.V. Georgakis, A. Younes, D. Jones, and L.J. Medeiros Expression of heat-shock protein-90 in non-Hodgkin's lymphomas Mod. Pathol. 18 10 2005 1343 1349
38. Y. Wang, and S.R. McAlpine N-terminal and C-terminal modulation of Hsp90 produce dissimilar phenotypes Chem. Commun. Camb. Engl. 51 8 2014 1410 1413
39. H. Zhao, E. Moroni, G. Colombo, and B.S. Blagg Identification of a new scaffold for Hsp90C-terminal inhibition ACS Med. Chem. Lett. 5 1 2014 84 88
40. H. Zhao, G. Garg, J. Zhao, E. Moroni, A. Girgis, L.S. Franco, S. Singh, G. Colombo, and B.S. Blagg Design, synthesis and biological evaluation of biphenylamide derivatives as Hsp90C-Terminal Inhibitors Eur. J. Med. Chem. 89 2015 442 466